Epkinly Market Report 2026

Epkinly Market Overview

• The Epkinly market growth in the historic period has been driven by rising incidence of non-hodgkin lymphoma, limitations of conventional chemotherapy • Market expansion is supported by growing adoption of immuno-oncology therapies, expanding clinical indications for bispecific antibodies • Growth Driver: Rising Demand For Targeted Therapies Drives Growth Of The Market • Market Trend: Regulatory Approvals Drive Innovation In The Market Enhancing Treatment Options For Follicular Lymphoma • North America was the largest region in 2025 and Europe is the fastest growing region.

What Is Covered Under Epkinly Market?

Epkinly (also known by its generic name epcoritamab) is a monoclonal antibody used in the treatment of certain types of cancer, particularly relapsed or refractory B-cell malignancies such as diffuse large B-cell lymphoma (DLBCL) and other non-Hodgkin lymphoma (NHL) subtypes. It works by targeting and binding to CD3, a protein found on T cells, and CD20, a protein found on B cells, which helps the immune system recognize and destroy cancerous cells. The main types of indications in epkinly are relapsed or refractory diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBL), and indolent lymphoma. Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) refers to DLBCL that either returns after initial treatment (relapsed). It includes various routes of administration, such as intravenous (IV) and subcutaneous (SC), and is distributed through hospital pharmacies, retail pharmacies, specialty pharmacies, and online pharmacies.

What Is The Epkinly Market Growth Forecast?

The growth in the forecast period can be attributed to growing adoption of immuno-oncology therapies, expanding clinical indications for bispecific antibodies, improved patient outcomes data, increasing oncology healthcare spending, expansion of specialty cancer centers. Major trends in the forecast period include bispecific antibody immunotherapies, expansion of t-cell engaging oncology drugs, focus on relapsed and refractory lymphomas, subcutaneous oncology drug administration, personalized hematologic cancer treatment.

Global Epkinly Market Segmentation

1) By Indication: Relapsed Or Refractory Diffuse Large B-Cell Lymphoma (DLBCL), High-Grade B-Cell Lymphoma (HGBL), Indolent Lymphoma 2) By Route Of Administration: Intravenous (IV), Subcutaneous (SC) 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, Online Pharmacies

What Is The Driver Of The Epkinly Market?

The growing demand for targeted therapies is anticipated to drive the expansion of the epkinly market in the future. Targeted therapies are precise treatments that block specific molecules driving disease, especially cancers, with fewer side effects than traditional treatments. Targeted therapies are increasing due to their ability to provide more effective, personalized treatments with fewer side effects. Epkinly (epcoritamab) is used in targeted therapy for relapsed or refractory B-cell non-Hodgkin lymphoma by binding CD3 on T cells and CD20 on B cells, directing the immune system to destroy cancerous B cells. For instance, in October 2024, according to the National Health Service, a UK-based government department, in 2023/24, 14.5% of HRT (hormone replacement therapy) items were associated with an HRT prescription prepayment certificate (PPC). By June 2024, this proportion had risen to 21%, compared to 9.7% in June 2023. Therefore, the rising demand for targeted therapies is driving the growth of the epkinly industry.

Key Players In The Global Epkinly Market

Major companies operating in the epkinly market are AbbVie Inc., Genmab A/S.

Global Epkinly Market Trends and Insights

The Key trends in the epkinly market include obtaining regulatory approvals for innovative therapies, such as bispecific antibody therapies, to enhance treatment efficacy and expand therapeutic options. Bispecific antibody therapies are a type of immunotherapy that involve antibodies engineered to bind to two different antigens or targets simultaneously. For instance, in June 2024, AbbVie Inc., a US-based biotech company, received FDA approval for EPKINLY (epcoritamab-bysp), the first bispecific antibody for adults with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. This innovative treatment engages the immune system by targeting CD20 and CD3, leading to an impressive overall response rate of 82% in clinical trials. Administered subcutaneously with a step-up dosing regimen, EPKINLY offers a new option for patients facing limited alternatives. This approval marks a significant advancement in the management of follicular lymphoma, providing hope for improved patient outcomes.

What Are Latest Mergers And Acquisitions In The Epkinly Market?

In June 2024, AbbVie Inc., a US-based biotech company, partnered with Genmab A/S to jointly develop and commercialize innovative bispecific antibody therapies, including epcoritamab. By combining Genmab's advanced antibody technology with AbbVie's clinical expertise, the partnership seeks to advance treatment options. Genmab A/S is a Denmark-based biotechnology company actively involved in the development and commercialization of Epkinly (epcoritamab), a bispecific antibody.

Regional Insights

North America was the largest region in the epkinly market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Epkinly Market?

The epkinly market consists of sales of products including rituxan (rituximab), polivy (polatuzumab vedotin), kymriah (tisagenlecleucel), yescarta (axicabtagene ciloleucel), and gazyva (obinutuzumab). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Epkinly Market Report 2026?

The epkinly market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the epkinly industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.